Gutenberg Research
  • Home
  • Models
  • Education
    • Cooperative Education Program >
      • Enroll Today >
        • Program Enrollment (Virtual)
        • Program Enrollment (Bootcamp - Boston)
        • Program Enrollment (Bootcamp - New York)
      • Training Hub (Winter'22-'23) >
        • Meetings >
          • Kick-off Call/Orientation (Winter'22-'23)
          • Meeting 1: Building the Model (Winter'22-'23)
          • Meeting 2: Entering Your Forecast Into The Model (Winter'22-'23)
          • Meeting 3: Target Valuation (Winter'22-'23)
          • Meeting 4: Live Starbucks Release (Winter'22-'23)
          • Meeting 5: Live FOMC Policy Release & ERP Update (Winter'22-'23)
        • Classes >
          • Class 1 - Introduction to Financial Modeling (Winter'22-'23)
          • Class 2 - Building the Income Statement (Winter'22-'23)
          • Class 3 - Balance Sheet and Cash Flow Modeling (Winter'22-'23)
          • Class 4 - Model Calibration & Forecasting (Winter'22-'23)
          • Class 5 - The DCF Inputs: Beta, ERP, CAPM, & WACC (Winter'22-'23)
          • Class 6 - Discounted Cash Flow Valuation (Winter'22-'23)
          • Class 7 - Market Multiple-Based Valuation (Winter'22-'23)
          • Class 8 - How to Use Your Earnings Model (Winter'22-'23)
    • Books >
      • Procrastinator's Guide - SBUX >
        • Templates - SBUX
      • Book Registration - Third Edition >
        • Templates - Third Edition
      • Book Registration - Second Edition >
        • Templates - Second Edition
  • About
    • Contact
    • Email Distribution Sign-up
    • Terms of Use
    • Privacy Policy

Jazz Pharma PLC (NASDAQ:JAZZ) Earnings Model


Models From Our Community 

Contributor Model by: Frank DePinto​
Last Update: November 20, 2016
View on Jazz: Bearish
Summary of Model Estimates: Updated Q32016 financials and lowered assumptions for 2017 revenue and EPS assumptions. According to commentary in the 10-K, Jazz is facing increasing threats from generic competition. The firm is also too reliant for my liking on sales of Xyrem, the primary drug facing generic competition. I also don't believe that Jazz is developing drugs in areas that are poised for tremendous patient growth or areas of unmet medical need. It seems like a majority of their clinical trial outlook is related to new indications for existing drugs in their portfolio. All in all, I don't necessarily have the most upbeat outlook for Jazz Pharmaceuticals for FY2017.
Click here to visit Frank's contributor page.
Frank DePinto JAZZ Model.xlsx
File Size: 88 kb
File Type: xlsx
Download File

Submit a Jazz Pharma Model

Gutenberg Research is a media and education company. The information presented on our website and within Gutenberg Research models, files, or other content does not represent investment advice. Data and information presented on this website, or on third party websites posted by us, within our models, files, and other content is for demonstration only, and is presented “as is”. Neither Gutenberg Research nor any Gutenberg Research agents or associates are liable for any errors, delays, incompleteness of data presented, or for actions taken based on reliance on any information contained on this website or within Gutenberg Research models or other content. Investors should consult a professional investment adviser prior to making investment decisions. By accessing this site and/or receiving our models or other content you are deemed to have read and agreed to our Terms of Use posted on this website. This website uses Cookies, refer to our Privacy Policy for details. The Gutenberg Research logo is among the registered and unregistered trademarks of Gutenberg Research LLC. © Gutenberg Research LLC 2023. All Rights Reserved.